XBIO (Xenetic Biosciences) ROCE %: -27.99% (As of Mar. 2026)

What is Xenetic Biosciences ROCE %?

Xenetic Biosciences XBIO -0.84% 83 ROCE % is -27.99% as of Mar. 2026. GuruFocus rates XBIO with a GF Score™ of 83/100 and a GF Value™ of $4.18 (Possible Value Trap). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Xenetic Biosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -27.99%.

Xenetic Biosciences (NAS:XBIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Xenetic Biosciences ROCE % Related Terms

Xenetic Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences ROCE % Chart

Xenetic Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-37.52

-41.93

-38.53

-53.21

-42.30

Xenetic Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-67.71	-60.50	-51.86	-43.90	-27.99

83GF Score

Xenetic Biosciences Inc XBIO

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Xenetic Biosciences ROCE % Calculation

Xenetic Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-2.835	/	( ( (6.901 - 0.894)	+	(8.364 - 0.968) )	/ 2 )
	=	-2.835	/	( (6.007	+	7.396)	/ 2 )
	=	-2.835	/	6.7015
	=	-42.30 %

Xenetic Biosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-2.008	/	( ( (8.364 - 0.968)	+	(7.909 - 0.958) )	/ 2 )
	=	-2.008	/	( ( 7.396	+	6.951 )	/ 2 )
	=	-2.008	/	7.1735
	=	-27.99 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -27.99% mean?

Xenetic Biosciences (XBIO) has a ROCE % of -27.99% as of Mar. 2026.

Is Xenetic Biosciences' ROCE % too high?

Xenetic Biosciences' current ROCE % is -27.99%. Overall, Xenetic Biosciences has a GF Score™ of 83/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Xenetic Biosciences' ROCE % compare to PCSA and SILO?

Xenetic Biosciences' ROCE % of -27.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Biotechnology company?

A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. Xenetic Biosciences's current ROCE % is -27.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Xenetic Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.18, compared to a current price of $2.95 — trading 29.5% below its estimated fair value. The current ROCE % is -27.99%. Xenetic Biosciences' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current ROCE % is -27.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued. The current stock price of $2.95 is trading 29.5% below its estimated GF Value™ of $4.18. GuruFocus considers Xenetic Biosciences to be Possible Value Trap.

Key valuation signals for XBIO:

ROCE %: -27.99%
GF Value™: $4.18 vs. price of $2.95 (29.5% below fair value)
GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies PCSA SILO LIMN ASBP TCRT BCAB CNSP SYBX ELAB GNPX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 945 Concord Street, Framingham, MA, USA, 01701

Website https://www.xeneticbio.com

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

83GF Score

Get the complete analysis for XBIO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.95

Price

$4.18

GF Value

View XBIO Analysis

See ROCE % data for all stocks →